Clinical Trial Update: A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating abemaciclib in combination with another anti-cancer drug in non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-small Cell Lung | Phase 1 | Status: COMPLETED | Results posted: 2020-09-11